Christopher Hren

Christopher Hren has a diverse work experience spanning various roles and industries. Christopher currently holds the position of Vice President of Corporate Development and Operations at Matchpoint Therapeutics since August 2021. Prior to that, they worked as a Senior Principal at Kendall Advisory from May 2020 to August 2021.

From April 2017 to January 2020, Christopher was the Senior Director of Corporate Development at Decibel Therapeutics. Before that, they had an extensive career at Biogen, starting as a Senior Manager of Global Hemophilia Marketing from November 2010 to November 2011. Christopher then held positions such as Senior Product Manager of US Hemophilia Marketing, Associate Director of US Hemophilia Marketing, and Associate Director of Corporate Strategy at Biogen. Christopher also worked as a Manager of Global Hemophilia Marketing and an Intern in Strategic Commercial Analytics at Biogen Idec from May 2009 to November 2010.

Christopher's professional journey began at Eidetics - A Division of Quintiles Transnational, where they worked as both a Senior Research Manager and a Research Manager from May 2004 to August 2008. Prior to that, they gained experience as a Patent Law Clerk at Mils and Onello, LLP from June 2003 to May 2004.

Christopher Hren completed their education in a chronological manner, beginning in 2000. Christopher attended Boston University from 2000 to 2004, where they earned their Bachelor of Arts (BA) degree in Economics and Philosophy. Following this, they pursued higher education at the Questrom School of Business, also at Boston University, from 2008 to 2010. During this period, they obtained a Master of Business Administration (MBA) degree with a specialization in Health Sector Management and Entrepreneurship.